Brief: Crescita Therapeutics reports positive topline results of phase 2 clinical trial to treat plaque psoriasis

Crescita Therapeutics

18/09/2017 12:31

Sept 18 (Reuters) - Crescita Therapeutics Inc  CTX.TO  
    * Crescita Therapeutics reports positive topline results of 
phase 2 clinical trial for the treatment of plaque psoriasis 
    * Crescita Therapeutics Inc - trial demonstrated 
statistical significance in achievement of its primary endpoint 
    * Crescita Therapeutics Inc - no unanticipated safety 
signals were noted in the trial 
    * Crescita - phase 2 results to be evaluated in anticipation 
of end-of-phase 2 meeting with U.S. FDA to discuss advancement 
to phase 3 
    * Crescita Therapeutics Inc - received positive topline 
results from a phase 2 clinical trial in patients with plaque 
psoriasis 
    * Crescita Therapeutics - licensing revenues would be shared 
between co and partners; co's share would reflect its 
contribution of patented formulations 
 
Source text for Eikon:  ID:nPn4HJyfVa  
Further company coverage:  CTX.TO  
 
 (((Bangalore.newsroom@thomsonreuters.com;);))